PULMATRIX INC (PULM)
US74584P3010 - Common Stock
PULM gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. The financial health of PULM is average, but there are quite some concerns on its profitability. PULM is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year PULM has reported negative net income.
PULM had a negative operating cash flow in the past year.
In the past 5 years PULM always reported negative net income.
PULM had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
PULM's Return On Assets of -41.59% is in line compared to the rest of the industry. PULM outperforms 47.18% of its industry peers.
With a Return On Equity value of -78.48%, PULM perfoms like the industry average, outperforming 45.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.59% | ||
| ROE | -78.48% | ||
| ROIC | N/A |
ROA(3y)-42.44%
ROA(5y)-47.01%
ROE(3y)-62.76%
ROE(5y)-91.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PULM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PULM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PULM has been increased compared to 1 year ago.
The number of shares outstanding for PULM has been increased compared to 5 years ago.
There is no outstanding debt for PULM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
PULM has an Altman-Z score of -12.20. This is a bad value and indicates that PULM is not financially healthy and even has some risk of bankruptcy.
PULM's Altman-Z score of -12.20 is on the low side compared to the rest of the industry. PULM is outperformed by 77.95% of its industry peers.
There is no outstanding debt for PULM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.2 |
ROIC/WACCN/A
WACC9.29%
2.3 Liquidity
PULM has a Current Ratio of 5.33. This indicates that PULM is financially healthy and has no problem in meeting its short term obligations.
PULM has a Current ratio of 5.33. This is in the better half of the industry: PULM outperforms 68.72% of its industry peers.
PULM has a Quick Ratio of 5.33. This indicates that PULM is financially healthy and has no problem in meeting its short term obligations.
PULM has a better Quick ratio (5.33) than 70.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.33 | ||
| Quick Ratio | 5.33 |
3. Growth
3.1 Past
PULM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.30%, which is quite impressive.
PULM shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.13%.
Measured over the past years, PULM shows a very strong growth in Revenue. The Revenue has been growing by 117.48% on average per year.
EPS 1Y (TTM)29.3%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q50%
Revenue 1Y (TTM)20.13%
Revenue growth 3Y-16.71%
Revenue growth 5Y117.48%
Revenue growth Q2Q28.77%
3.2 Future
PULM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.73% yearly.
PULM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 40.85% yearly.
EPS Next Y-18.91%
EPS Next 2Y-14.37%
EPS Next 3Y12.08%
EPS Next 5Y22.73%
Revenue Next Year1%
Revenue Next 2Y1%
Revenue Next 3Y33.81%
Revenue Next 5Y40.85%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PULM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PULM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PULM's earnings are expected to grow with 12.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.37%
EPS Next 3Y12.08%
5. Dividend
5.1 Amount
PULM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PULMATRIX INC
NASDAQ:PULM (4/25/2024, 7:13:05 PM)
2.08
+0.06 (+2.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.59M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.59% | ||
| ROE | -78.48% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.33 | ||
| Quick Ratio | 5.33 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)29.3%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-18.91%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)20.13%
Revenue growth 3Y-16.71%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y